We demonstrated that the tumor LS value, as measured by SWE before combination treatment with anti-PD-1 antibodies plus lenvatinib, was a convenient predictor of tumor progression in patients with advanced HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.